Tailored Therapeutics Abreos has developed Veritope technology for monitoring active biologic drug levels to enable personalized dosing decisions, presenting a clear opportunity to partner with biotech firms and hospitals aiming to optimize biologic therapies and improve patient outcomes.

Diagnostics Expansion Past collaborations with LifeAssays AB and development of diagnostic kits indicate a path to expand into diagnostic partnerships and co-development agreements with autoimmune and other biologic-focused indications.

MS and Autoimmune Focus Existing moNATor launch for monitoring natalizumab in MS demonstrates traction in autoimmune disease monitoring, suggesting a sales angle targeting neurology clinics, MS centers, and payers seeking assay-based dosing guidance.

Early Clinical Adoption The Have I Had It COVID-19 quantitative test showcases readiness to deploy rapid, quantitative assays, signaling opportunities to introduce Veritope-based monitoring in acute-care and epidemiology-focused settings.

Strategic Partnerships A history of collaborations with ResearchDx and LifeAssays indicates a favorable pattern for channel partnerships, licensing opportunities, and co-marketing with diagnostic and CROs to accelerate market entry.